Vilga Financial Planning LLC Buys New Shares in United Therapeutics Corporation $UTHR

Vilga Financial Planning LLC purchased a new stake in United Therapeutics Corporation (NASDAQ:UTHR) during the 3rd quarter, HoldingsChannel.com reports. The fund purchased 20,003 shares of the biotechnology company’s stock, valued at approximately $10,839,000. United Therapeutics makes up 6.5% of Vilga Financial Planning LLC’s portfolio, making the stock its 2nd biggest holding.

A number of other institutional investors and hedge funds have also recently modified their holdings of UTHR. BlackRock Inc. bought a new stake in shares of United Therapeutics in the 2nd quarter valued at $2,868,735,000. Jupiter Topco LLC bought a new position in United Therapeutics during the second quarter worth $450,140,000. Bank of New York Mellon Corp acquired a new stake in United Therapeutics in the second quarter worth $159,522,000. Caisse de depot et placement du Quebec acquired a new stake in United Therapeutics in the second quarter worth $154,304,000. Finally, Legal & General Group Plc bought a new stake in United Therapeutics in the second quarter valued at $112,209,000. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Price Performance

UTHR opened at $532.78 on Friday. United Therapeutics Corporation has a fifty-two week low of $409.07 and a fifty-two week high of $609.35. The firm has a market capitalization of $22.85 billion, a PE ratio of 19.06, a P/E/G ratio of 2.73 and a beta of 0.49. The company’s 50-day moving average is $511.37 and its 200 day moving average is $539.93.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. The business had revenue of $783.30 million during the quarter, compared to the consensus estimate of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The company’s quarterly revenue was down 1.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $6.41 EPS. As a group, analysts expect that United Therapeutics Corporation will post 26.21 EPS for the current year.

Analyst Ratings Changes

UTHR has been the topic of a number of research analyst reports. Weiss Ratings cut shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, August 27th. The Goldman Sachs Group initiated coverage on United Therapeutics in a report on Thursday, September 24th. They issued a “sell” rating and a $321.00 price target on the stock. Bank of America lowered their target price on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. Cantor Fitzgerald reiterated an “overweight” rating on shares of United Therapeutics in a report on Thursday, October 1st. Finally, Morgan Stanley increased their target price on United Therapeutics from $515.00 to $566.00 and gave the stock an “equal weight” rating in a report on Wednesday. Eleven analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $627.31.

Insider Activity

In related news, CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $516.06, for a total transaction of $4,902,570.00. Following the completion of the sale, the chief executive officer owned 324,443 shares in the company, valued at approximately $167,432,054.58. This represents a 2.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders sold a total of 364,728 shares of company stock worth $187,920,726 over the last 90 days. 8.60% of the stock is owned by insiders.

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH) and other serious cardiopulmonary conditions. The company’s products include Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable form of treprostinil; Orenitram, an oral treprostinil product; and Adcirca, a tadalafil-based PAH treatment.

United Therapeutics markets its therapies primarily in the United States and internationally through commercial and regulatory activities in additional markets.